Department of ENT Surgery, Queen Elizabeth University Hospital, 1345 Govan Rd, Glasgow, G51 4TF, UK.
University of Glasgow, Glasgow, UK.
Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3705-3715. doi: 10.1007/s00405-021-07233-2. Epub 2022 Feb 2.
To evaluate the utility of various pre-treatment prognostic scoring systems for overall survival (OS) in laryngeal cancer, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), modified Glasgow Prognostic Score (mGPS) and systemic immune-inflammatory index (SIII).
We undertook a retrospective 5-year study of 220 patients with laryngeal squamous cell carcinoma undergoing active treatment.
On multivariate analysis, low NLR (≤ 2.415, p = 0.001, OR 3.851), low PLR (≤ 269.855, p = 0.002, OR 5.520), high LMR (> 2.225, p < 0.001, OR 0.458) and low SIII (≤ 1144.465, p = 0.003, OR 3.673) were significantly associated with improved OS, accounting for confounding factors of tumour subsite, T-stage and performance status. C-reactive protein (CRP) alone (p = 0.264) and mGPS (p = 0.350) were not significantly associated with OS.
NLR, PLR, LMR and SIII represent inexpensive, easily obtainable adjuvant decision-making tools which could help tailor individualised treatment regimes. Further investigation into the utility of combination scores and the role of different laryngeal subsites may be of interest.
评估中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）、改良格拉斯哥预后评分（mGPS）和全身免疫炎症指数（SIII）等各种预处理预后评分系统在喉癌总生存（OS）中的作用。
我们对 220 例接受积极治疗的喉鳞状细胞癌患者进行了一项回顾性 5 年研究。
多因素分析显示，低 NLR（≤2.415，p=0.001，OR 3.851）、低 PLR（≤269.855，p=0.002，OR 5.520）、高 LMR（>2.225，p<0.001，OR 0.458）和低 SIII（≤1144.465，p=0.003，OR 3.673）与 OS 改善显著相关，可解释肿瘤部位、T 分期和功能状态等混杂因素。单独 C 反应蛋白（CRP）（p=0.264）和 mGPS（p=0.350）与 OS 无显著相关性。
NLR、PLR、LMR 和 SIII 是廉价、易于获得的辅助决策工具，可帮助制定个体化治疗方案。进一步研究联合评分的效用以及不同喉亚部位的作用可能会很有意义。
